Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310140 · ClinicalTrials.gov registry record
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 14
- Enrollment target
NCT01310140: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT01310140 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01310140 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Studies have shown that people with certain disorders have an increased risk of developing a condition called Metabolic Syndrome (MS). In this study, the investigators want to learn more about MS among people staying in the hospital for treatment of Major Depressive Disorder (MDD) and also Major Depressive Disorder with Psychotic Features (MDpsy). The investigators also want to learn more about a stress hormone called cortisol that is made in the body. Those who take part in this study will answer some questionnaires, be given some psychiatric interviews, and have some blood taken along with a urine sample. The investigators believe that patients in the hospital with MDpsy will have higher baseline rates of MS factors, cortisol levels, dexamethasone non-suppression, and insulin resistance, compared with MDD alone.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01310140
The ClinicalTrials.gov registry entry for NCT01310140 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01310140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01310140 about?
NCT01310140 is a clinical study titled "Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features". Studies have shown that people with certain disorders have an increased risk of developing a condition called Metabolic Syndrome (MS). In this study, the investigators want to learn more about MS among people staying in the hospital for treatment of Major Depressive Disorder (MDD) and also Major Dep...
What is the current status of trial NCT01310140?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2011-01. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT01310140?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.